Quantum-Si incorporated
NASDAQ:QSIBiotechnology
+$0.05 today
- Market cap
- $201.80M
- Beta
- 3.17
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.48
Volume 5.35M
Average 5.64M
QSI EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Quantum-Si incorporatedNASDAQ: QSI
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$20.57M, compared with -$18.26M a year earlier. Trailing-twelve-month EBITDA was -$99.13M.
Context
- EBITDA amounted to 3974.8% of revenue in FY2025, up 824.1 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of -$85.21M (+12.0%) for the fiscal year ending Dec 2026, a step up from the -0.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$20.57M-25.2% QoQ
- Last fiscal yearDec 2025
- -$96.83M-0.5% YoY
- LTMMar 2026
- -$99.13M-3.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -12.6% | +14.6% | +27.2 pp |
| 1 year | -0.5% | +12.0% | +12.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (96.83M) USD
- Year-over-year change
- -0.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (96.83M) | -0.5% |
| FY2024 | 2024-12-31 | (96.35M) | -5.0% |
| FY2023 | 2023-12-31 | (91.8M) | +17.9% |
| FY2022 | 2022-12-31 | (111.77M) | -19.0% |
| FY2021 | 2021-12-31 | (93.94M) | — |
EBITDA vs competitors
How QSI compares with its peers on the latest reported figures
- QSI's LTM Mar 2026 EBITDA of -$99.13M is the 4th highest of the 11 companies compared; the peer median is -$142.71M.
- Its year-over-year change of -3.1% is the 5th highest of 10, against a peer median of -17.1%.
- EBITDA amounts to 5352.8% of revenue for QSI, versus a peer median of 249.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$39.05M | — | — | — |
| LTM Mar 2026 | -$83.2M | +13.7% | — | 105.1% | |
| LTM Mar 2026 | -$88.27M | +2.7% | — | 245200.0% | |
| LTM Mar 2026 | -$99.13M | -3.1% | — | 5352.8% | |
| LTM Mar 2026 | -$111.17M | -19.0% | — | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | -$125.94M | -65.1% | — | — |
| LTM Mar 2026 | -$159.48M | -49.1% | — | — | |
| LTM Mar 2026 | -$190.1M | -38.9% | — | — | |
| LTM Mar 2026 | -$193.41M | -17.1% | — | — | |
| LTM Mar 2026 | -$194.47M | +21.0% | — | — | |
| LTM Mar 2026 | -$230.8M | +3.4% | — | 249.3% | |
| Peer median (excluding QSI) | -$142.71M | -17.1% | — | 249.3% | |
Competitors are the stored peer set for QSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.08M | 3.06M | 2.44M |
| Cost of Revenue | 0 | 0 | 594K | 1.46M | 1.28M |
| Gross Profit | 0 | 0 | 488K | 1.6M | 1.15M |
| Gross Margin | — | — | 45.1% | 52.3% | 47.3% |
| Research & Development | 46.58M | 72.06M | 67.03M | 59.64M | 53.76M |
| Selling, General & Admin | 50.33M | 42.3M | 44.63M | 50.54M | 44.75M |
| Operating Expenses | 96.91M | 123.84M | 111.66M | 110.18M | 98.51M |
| Depreciation & Amortization | 1.04M | 2.58M | 4.16M | 4.6M | 4.45M |
| EBITDA | (93.94M) | (111.77M) | (91.8M) | (96.35M) | (96.83M) |
| EBITDA Margin | — | — | -8484.7% | -3150.8% | -3974.8% |
| Operating Income | (96.91M) | (123.84M) | (111.17M) | (108.58M) | (97.36M) |
| Operating Margin | — | — | -10274.6% | -3550.6% | -3996.7% |
| Interest Income | 0 | 0 | 0 | 0 | 8.96M |
| Interest Expense | 5K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.92M | (8.6M) | 15.21M | 7.63M | (3.92M) |
| Income Before Tax | (94.99M) | (132.44M) | (95.96M) | (100.95M) | (101.28M) |
| Pre-Tax Margin | — | — | -8868.8% | -3301.2% | -4157.7% |
| Income Tax Expense | 0 | 0 | 0 | 56K | 58K |
| Net Income | (94.99M) | (132.44M) | (95.96M) | (101.01M) | (101.34M) |
| Net Margin | — | — | -8868.8% | -3303.0% | -4160.1% |
| EPS (Basic) | (1.19) | (0.95) | (0.68) | (0.71) | (0.51) |
| EPS (Diluted) | (1.19) | (0.95) | (0.68) | (0.71) | (0.51) |
| Weighted Avg Shares | 79.58M | 139.26M | 141.3M | 143.2M | 197.77M |
| Weighted Avg Shares (Diluted) | 79.58M | 139.26M | 141.3M | 143.2M | 197.77M |
Quantum-Si incorporated
NASDAQ:QSI
Intrinsic Alpha fair value
Locked
Current Price
$1.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.